目的 观察康莱特注射液对晚期肝癌患者血清甲胎蛋白（AFP）的抑制作用和对患者体力状况的影响。方法 选择62例经明确诊断的晚期肝癌患者，分为两组，对照组给予保肝、生物反应调节剂及支持对症治疗，治疗组加用康莱特注射液100 mL静脉滴注。结果 对照组治疗后AFP受益率为54.84%，治疗组为87.10%；两组卡氏评分（KPS）受益率分别为61.29%、83.87%，两者差异均有统计学意义（P＜0.05）。结论 康莱特注射液可明显降低晚期肝癌患者外周血AFP水平，改善患者体力状态，提高患者生活质量。

Objective To observe the inhibition of Kanglaite Injection on serum alpha-fetoprotein (AFP) and the influence on physical condition of advanced hepatocellular carcinoma patients. Methods The 62 patients with advanced hepatocellular carcinoma were randomly divided into two groups. The control group was given liver-protected drugs and biological reaction regulator with the symptomatic treatment, while the treatment group was given 100 mL Kanglaite Injection via iv infusion. Results After treatment the benefit ratio of AFP in the control group was 54.84% and that in the treatment group was 87.10%. The benefit ratios of Karnofsky (KPS) score in the two groups were 61.29% and 83.87% both significant difference (P<0.05). Conclusion Kanglaite Injection could obviously decrease the AFP level in peripheral blood of advanced hepatocellular carcinoma patients and improve the physical state and life quality of the advanced hepatocellular carcinoma patients.